Xcout Intel
Omniox, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Omniox, Inc. among drug discovery companies — ranked by similarity to what Omniox, Inc. actually does, not by market-cap band.
Subscribe to see Omniox, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Omniox, Inc.
Omniox, Inc. is an early-stage biopharmaceutical company located in San Francisco, California, focused on developing new medicines for hypoxic diseases.
Omniox, Inc. at a glance
Omniox, Inc. is a drug discovery company headquartered in United States. It has raised at least $27.1M across the 2 funding rounds on record. Its most recent funding round raised $24.1M in July 2016. Xcout tracks 3 named people at Omniox, Inc., including Jonathan Winger (CEO).
Omniox, Inc. leadership
- Jonathan WingerCEO
- Jonathan WingerCo-Founder and CEO
- Julia SimmonsSenior Director, Controller
Omniox, Inc. funding rounds
At least $27.1M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $24.1M | — | |
| — | $3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Omniox, Inc. competitors
Ranked by semantic similarity — how close each company is to Omniox, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar drug discovery company
KayoThera, Inc. is an early-stage, preclinical therapeutics company headquartered in Seattle, Washington. The firm focuses on developing first-in-class, oral, small molecule treatments.
Similar drug discovery company
Kinoxis Therapeutics Pty Ltd is an Australian-based, clinical-stage biotechnology company that develops first-in-class therapeutics targeting ALOX15 to address central nervous system (CNS) diseases.
Similar drug discovery company
Glycomine, Inc. is a biotherapeutics company focused on developing replacement therapies and treatments for serious rare genetic diseases, operating out of major life science hubs in San Francisco and Boston.
Similar drug discovery company
AllIn Bio is a drug discovery company headquartered in Woodside, California. The firm is developing a precision-immunology approach designed to treat the root cause of chronic inflammatory diseases.
Similar drug discovery company
OncoMyx Therapeutics, Inc. is a biotechnology company headquartered in Phoenix, Arizona, that develops innovative oncolytic immunotherapies to target and destroy tumors.
Similar drug discovery company
AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company headquartered in Stockholm. The company focuses on developing novel drugs designed to treat heart failure.
Similar drug discovery company
LUCA Science is a pre-clinical stage biotechnology company that develops functional mitochondria as therapeutic agents to treat damaged tissues and organs. The company utilizes a proprietary method to isolate functional mitochondria, combining it with advanced drug delivery and formulation technology to create storable biopharmaceutical agents.
Similar drug discovery company
Vivacelle Bio, Inc. is a Chicago-based developmental-stage biotechnology company pioneering innovative intravenous fluid therapies for treating conditions like sepsis and organ failure.
Similar drug discovery company
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients. Founded in 2024, the company is based in Morris Plains, New Jersey.
Similar drug discovery company
ApoGlyx is a Swedish life science company located in Lund that focuses on developing innovative medicines for acute systemic inflammatory diseases such as sepsis and acute pancreatitis.
Biopharmaceuticals
Altay Therapeutics, Inc. is a biotechnology company founded in 2019 and headquartered in the San Francisco Bay Area, California. The company focuses on developing therapeutics within the biotechnology sector.
Biopharmaceuticals
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Omniox, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Omniox, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →